Skip to main content

Laser Interstitial Thermal Therapy + Lomustine

Laser Interstitial Thermal Therapy (LITT) and Lomustine (CCNU) for Recurrent Glioblastoma

  • RegistryNCT07145112
  • PhasePhase 1
  • StatusRecruiting
  • ConditionRecurrent Glioblastoma
  • SponsorUniversity of California, Davis
How LITT + Lomustine works1 min

The drug

What is being tested.

The LITT procedure is performed per standard of care under general anesthesia using a stereotactic neurosurgical approach where a laser catheter is precisely inserted into the tumor under MRI guidance. Real-time MRI thermometry is used to ensure controlled tumor ablation while minimizing damage to adjacent structures.

Patients typically undergo postoperative MRI to assess treatment response, and most can be discharged within 24-48 hours, facilitating early initiation of adjuvant therapy. Approximately 7 days following LITT, lomustine is administered per standard of care on Day 1 for a total of one cycle. Participants will be monitored for serious and non-serious adverse events (AE) starting from initiation of LITT per institutional practices.

The study

How the trial runs.

This is a phase 1 study evaluating the safety and feasibility of laser interstitial thermal therapy (LITT) followed by lomustine (CCNU) for recurrent glioblastoma in adults. The primary aim is to evaluate the safety of the combination of LITT plus lomustine based on the assessment of treatment-related adverse events and the feasibility of completing LITT + lomustine in the proposed timeframe.

The secondary aim is to assess overall survival for up to 2 years after the first dose of lomustine.

Live record on ClinicalTrials.gov →

Eligibility

Who the study is looking for.

  • Histologically confirmed World Health Organization (WHO) 2021 defined glioblastoma. A pathology report constitutes adequate documentation of histology for study inclusion.
  • Radiographic demonstration of disease progression following prior therapy.
  • Patients having undergone recent resection of recurrent or progressive tumor will be eligible as long as the patient has recovered from surgery. Evaluable or measurable disease following resection of recurrent tumor is not mandated for eligibility into the study.
  • Prior standard radiation for glioblastoma (short course 40 Gy, standard 60 Gy, and proton therapy are allowed).
  • Patients must have recovered from the effects of prior therapy.

Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.

For you, or someone you love

Whether or not this trial is the one, bring AI into your corner.

A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.

Start your 7-day free trial

Then $9 a month. Cancel anytime.

  • Every record in one place

    Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.

  • Read in plain words

    Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.

  • Ready for every appointment

    Ask about your own file, and walk in with questions for your oncologist or the trial team.

  • Your people, in the loop

    Share one profile with the family helping you, and with your doctors.

Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.

How these trials work: what Phase 1 actually is · common questions Not clinical evidence.

Not sure whether you would qualify?

Would this trial apply to me?

7-day free trial, then $9 a month. Cancel anytime.